- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04518306
Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension (GMRx2_PCT)
Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Placebo for the Treatment of Hypertension
Study Overview
Status
Conditions
Detailed Description
TRIAL DRUG:
GMRx2: single pill combination of telmisartan/amlodipine/indapamide Dose version 1: telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg Dose version 2: telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg I NDICATION: Hypertension
TRIAL TITLE:
Efficacy and safety of GMRx2 compared to placebo for the treatment of hypertension.
OBJECTIVES:
To investigate the efficacy and safety of GMRx2 compared to placebo for the treatment of hypertension.
INTERVENTION:
A 2-week single-blind placebo run-in will be followed by a 4-week double-blind period with randomization to GMRx2 dose version 1, GMRx2 dose version 2 or placebo.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Erin Corstanje
- Phone Number: +44 (0)7879192633
- Email: ecorstanje@george-medicines.com
Study Contact Backup
- Name: Suzanne Milne
- Phone Number: +19013900306
- Email: gmrx2gpm@georgeclinical.com
Study Locations
-
-
New South Wales
-
Castle Hill, New South Wales, Australia, 2154
- Castle Hill Medical Centre
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Hudson Institute of Medical Research
-
Geelong, Victoria, Australia, 3220
- Barwon Health, Geelong University Hospital
-
-
Western Australia
-
Bentley, Western Australia, Australia, 6102
- Curtin University
-
Perth, Western Australia, Australia, 6000
- Royal Perth Hospital
-
-
-
-
-
Kano, Nigeria
- Aminu Kano Teaching Hospital
-
-
Federal Capital Territory
-
Gwagwalada, Federal Capital Territory, Nigeria, 902101
- University of Abuja Teaching Hospital
-
-
-
-
-
Colombo, Sri Lanka, 10-01000
- Institute of Cardiology, National Hospital of Sri Lanka
-
Dehiwala, Sri Lanka, 10350
- Colombo South Teaching Hospital
-
Galle, Sri Lanka, 80000
- Karapitiya Teaching Hospital
-
Jaffna, Sri Lanka, 40000
- Jafna Teaching Hospital
-
Kandy, Sri Lanka, 20000
- Kandy National Hospital
-
Kurunegala, Sri Lanka, 60000
- Kurunegala Teaching Hospital
-
Ragama, Sri Lanka, 11010
- Colombo North Teaching Hospital
-
-
-
-
-
Romsey, United Kingdom, SO51 8EN
- Abbeywell Surgery
-
Wellingborough, United Kingdom, NN8 4RW
- Albany House Medical Centre
-
-
Cambridgeshire
-
Soham, Cambridgeshire, United Kingdom, CB7 5JD
- Steploe Medical Centre
-
-
Cornwall
-
Newquay, Cornwall, United Kingdom, TR7 1RU
- Newquay Medical
-
-
Leicestershire
-
Hinckley, Leicestershire, United Kingdom, LE10 2SE
- Burbage Surgery
-
-
London
-
Harrow, London, United Kingdom, HA3 7LT
- Belmont Health Centre
-
-
Somerset
-
Bristol, Somerset, United Kingdom, BS37 4AX
- West Walk Surgery
-
-
Surrey
-
Betchworth, Surrey, United Kingdom, RH3 7NJ
- Brockwood Medical Practice
-
-
West Midlands
-
Coventry, West Midlands, United Kingdom, CV3 6NF
- Lakeside Surgery
-
-
Wiltshire
-
Trowbridge, Wiltshire, United Kingdom, BA14 8LW
- Trowbridge Health Centre
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85018
- Elite Clinical Studies
-
Scottsdale, Arizona, United States, 85260
- Headlands Research
-
Tucson, Arizona, United States, 85712
- Quality of Life Medical & Research Centers, LLC
-
-
California
-
S. Gate, California, United States, 90280
- Valiance Clinical Research
-
Tarzana, California, United States, 91356
- Valiance Clinical Research
-
-
Florida
-
Brandon, Florida, United States, 33511
- Clinical Research of Brandon
-
Hialeah, Florida, United States, 33013
- Inpatient Research Clinic
-
Miami, Florida, United States, 33165
- New Horizon Research Center
-
Miami, Florida, United States, 33135
- Suncoast Research Group
-
Ocala, Florida, United States, 34471
- Ocala Research Institute
-
Palm Beach, Florida, United States, 33461
- Altus Research, Inc
-
Saint Petersburg, Florida, United States, 33173
- Suncoast Research Associates
-
Saint Petersburg, Florida, United States, 33709
- Accel Research
-
Sunrise, Florida, United States, 33351
- Precision Clinical Research
-
Tampa, Florida, United States, 33603
- Precision Research Center
-
-
Georgia
-
Snellville, Georgia, United States, 30078
- Buckhead Primary Care Research
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Meridian Clinical Research
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- The University of Tennessee Health Science Center
-
-
Texas
-
Houston, Texas, United States, 77036
- Synergy Groups Medical
-
Houston, Texas, United States, 77087
- Synergy Groups Medical
-
Missouri City, Texas, United States, 77459
- Synergy Groups Medical
-
North Richland Hills, Texas, United States, 76180
- North Hills Medical Research
-
-
Virginia
-
Portsmouth, Virginia, United States, 23703
- Meridian Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
At screening visit:
- Provided signed consent to participate in the trial.
- Adult aged ≥18 years.
- Low calculated CV risk according to local guidelines such that pharmacological BP-lowering treatment is not mandatory: e.g. Pooled Cohorts Equation 10-years ASCVD risk <10% in the USA.
Likely diagnosis of hypertension, defined as one or more of:
- automated SBP at this clinic visit according to trial methods (see Appendix 2) of ≥130mmHg on no BP lowering medicines or ≥120mmHg on 1 BP lowering medicine that will be stopped at this visit, OR
- documentation in last 6 months of office SBP ≥ 140 mmHg and/or DBP ≥ 90mmHg on no BP lowering medicines or SBP ≥ 130 mmHg and/or DBP ≥ 85mmHg on 1 BP lowering medicine that will be stopped at this visit, OR
- documentation in last 6 months of home SBP ≥ 130 mmHg and/or DBP ≥ 80mmHg on no BP lowering medicines or SBP ≥ 120 mmHg and/or DBP ≥ 75mmHg on 1 BP lowering medicine that will be stopped at this visit, OR
- documentation in last 6 months of ambulatory daytime SBP ≥ 130 mmHg and/or DBP ≥ 80mmHg on no BP lowering medicines or SBP ≥ 120 mmHg and/or DBP ≥ 75mmHg on 1 BP lowering medicine that will be stopped at this visit
- No contraindication to trial medications, including 2-weeks placebo run-in and 4-weeks randomized treatment period with GMRx2 (dose version 1 or 2) or placebo.
At randomization visit:
- Home seated mean SBP 130-154 mmHg in the week before the randomization visit.
- Adherence of 80-120% to placebo run-in.
- Tolerated placebo run-in.
- Adherence to home BP monitoring schedule: in the week before randomization, at least 6 measures (e.g. ≥2 sets of triplicate measures) including at least 1 morning and 1 evening each with ≥2 measures. Morning is defined as any measure in the am and evening as any measure in the pm. Morning and evening do not have to be same day.
Exclusion Criteria:
At screening visit:
- Receiving 2 or more BP-lowering drugs.
- Clinic seated mean SBP ≥160 mmHg and/or DBP ≥100 mmHg.
- Pregnant or had a positive pregnancy test or unwilling to undertake a pregnancy test during the trial and up to 30 days after the discontinuation of the trial medication or breastfeeding or of childbearing age and not using an acceptable method of contraception. Acceptable methods of birth control include hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (e.g. condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), or male partner sterilization. Contraception should be used for at least 1 month before the screening visit and until the end of trial participation.
- Not suitable for participation in a clinical trial according to local ethical or regulatory requirements related to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
- Contraindication, including hypersensitivity (e.g. anaphylaxis or angioedema), to any of the 3 trial medications.
- Current/history of transient ischemic attack, stroke, or hypertensive encephalopathy.
- Current/history of acute coronary syndrome, unstable angina, myocardial infarction, percutaneous transluminal coronary revascularization, or coronary artery bypass graft.
- Current/history of New York Heart Association class III and IV congestive heart failure.
- Current/history of a known secondary cause of hypertension, such as primary aldosteronism, renal artery stenosis, pheochromocytoma, or Cushing's syndrome.
- Current/history of substantially uncontrolled diabetes (HbA1c > 11.0%) within last three months.
- Current/history of end-stage renal disease or anuria or estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m2.
- Current/history of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times the upper limit of normal range within 6 months.
- Current concomitant illness or physical impairment or mental condition that in the judgment of the investigator could interfere with the effective conduct of the trial or constitutes a significant risk to the participants' well-being.
- Arm circumference that is too large (>55 cm) or too small (<20 cm) to allow accurate measurement of BP.
- Currently taking or might need during the trial, a concomitant treatment which is known to interact significantly with the trial medication: digoxin, lithium, diabetics receiving aliskiren, moderate and strong CYP3A4 inhibitors [e.g. ritonavir, ketoconazole, diltiazem], simvastatin >20 mg/day, immunosuppressants.
- Might need treatment with drugs that are prohibited during the trial: other antihypertensive drugs, endothelin receptor antagonists, neprilysin inhibitors, or other drugs that may affect BP (see Error! Reference source not found.).
- Current surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of trial drugs such as prior major gastrointestinal tract surgery (e.g. gastrectomy, lap band, or bowel resection) or acute flare of inflammatory bowel disease within one year.
- Individuals working >2-night shifts per week.
- Participated in any investigational drug or device trial within the previous 30 days.
- History of alcohol or drug abuse within 12 months.
At randomization visit:
- Unable to adhere to the trial procedures during the run-in period.
Any of the following which in the investigator's judgment may compromise the safety of the participant if randomized to the trial medications:
- High or low clinic BP levels even in the light of the values for home BP that are available for that participant. The exact levels of BP are not specified, since there is clinical uncertainty as to the relevance of BP levels which are high/low in clinic only; for example the clinical relevance of 'whitecoat hypertension' is uncertain.
- High or low home DBP levels. The exact levels of DBP are not specified, reflecting clinical uncertainty of for example isolated diastolic hypertension. However, home DBP values of >99 mmHg may typically be considered as requiring treatment intensification, and such participants would not be suitable for randomization.
- Any abnormal laboratory value which in the judgment of the investigator could interfere with the effective conduct of the trial or constitutes a significant risk to the participants' well-being.
- Fulfilling any of the exclusion criteria mentioned for the screening visit, when verified again at randomization visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo
|
Experimental: Triple ¼ (GMRx2)
Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
|
Oral tablets
|
Active Comparator: Triple ½ (GMRx2)
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
|
Oral tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in change in home seated SBP from baseline to Week 4
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in change in clinic seated mean SBP from baseline to Week 4
Time Frame: 4 weeks
|
4 weeks
|
Difference in change in clinic seated mean DBP from baseline to Week 4
Time Frame: 4 weeks
|
4 weeks
|
Percentage of participants with clinic seated mean SBP <140 and DBP <90 mmHg at Week 4
Time Frame: 4 weeks
|
4 weeks
|
Percentage of participants with clinic seated mean SBP <130 and DBP <80 mmHg at Week 4
Time Frame: 4 weeks
|
4 weeks
|
Difference in change in home seated mean DBP from baseline to Week 4
Time Frame: 4 weeks
|
4 weeks
|
Difference in change in trough home seated mean SBP from baseline to week 4
Time Frame: 4 weeks
|
4 weeks
|
Difference in change in trough home seated mean DBP from baseline to week 4
Time Frame: 4 weeks
|
4 weeks
|
Percentage of participants with home seated mean SBP <135 and DBP <85 mmHg at Week 4
Time Frame: 4 weeks
|
4 weeks
|
Percentage of participants with home seated mean SBP <130 and DBP <80 mmHg at Week 4
Time Frame: 4 weeks
|
4 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Safety Outcome
Time Frame: 4 weeks
|
Percentage of participants discontinued trial medication due to AE/SAE from baseline to Week 4
|
4 weeks
|
Secondary Safety Outcome 1
Time Frame: 4 weeks
|
Percentage of participants with an SAE from baseline to Week 4
|
4 weeks
|
Secondary Safety Outcome 2
Time Frame: 4 weeks
|
Percentage of participants with symptomatic hypotension from baseline to Week 4
|
4 weeks
|
Secondary Safety Outcome 3
Time Frame: 4 weeks
|
Percentage of participants with serum sodium concentration below 135 mmol/l at Week 4
|
4 weeks
|
Secondary Safety Outcome 4
Time Frame: 4 weeks
|
Percentage of participants with serum sodium concentration above 145 mmol/l at Week 4
|
4 weeks
|
Secondary Safety Outcome 5
Time Frame: 4 weeks
|
Percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 4
|
4 weeks
|
Secondary Safety Outcome 6
Time Frame: 4 weeks
|
Percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 4
|
4 weeks
|
Secondary Safety Outcome 7
Time Frame: 4 weeks
|
Percentage of participants with eGFR drop of over 30% from baseline to Week 4
|
4 weeks
|
Secondary Safety Outcome 8
Time Frame: 4 weeks
|
Percentage of participants with serum sodium <135mmol/l or >145 mmol/l, and/or serum potassium <3.5 mmol/l or >5.5mmol/l at week 4
|
4 weeks
|
Secondary Safety Outcome 9
Time Frame: 4 weeks
|
Percentage of participants with postural hypotension at Week 4
|
4 weeks
|
Secondary Safety Outcome 10
Time Frame: 4 weeks
|
Percentage of participants with postural hypertension at Week 4
|
4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anthony Rodgers, Professor, The George Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Sodium Chloride Symporter Inhibitors
- Amlodipine
- Telmisartan
- Indapamide
Other Study ID Numbers
- GMRx2-HTN-2020-PCT1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States